3rd Inflammatory Skin Disease Summit (ISDS 2018)

Secukinumab demonstrates long-term benefit in active psoriatic arthritis

Roshini Claire Anthony, 20190121140303

The benefits of the fully human monoclonal antibody secukinumab at doses of either 150 or 300 mg weekly in patients with active psoriatic arthritis are sustained even after 4 years, according to updated results of the FUTURE 2* study presented at the Inflammatory Skin Disease Summit (ISDS 2018).

Risankizumab improves skin appearance in patients with plaque psoriasis

Elaine Soliven, 20190119000000

Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).

Guselkumab tops secukinumab for moderate-to-severe plaque psoriasis

Roshini Claire Anthony, 20190117140302

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Abatacept fails to prevent psoriasis relapse after stopping ustekinumab

Pearl Toh, 20190116180010

Blocking costimulatory immune response with abatacept did not prevent psoriasis relapse after ustekinumab discontinuation, reveals a study presented at ISDS 2018.

JAK3 inhibitors zoom in as potential cure for spot baldness

Elvira Manzano, 20190116114000

Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.

Tralokinumab shows promise for AD

Audrey Abella, 20190115100000

The human monoclonal antibody tralokinumab significantly reduced skin colonization by Staphylococcus aureus (S. aureus) in adults with moderate-to-severe atopic dermatitis (AD), according to a study presented at ISDS 2018.

Crisaborole ointment reduces AD lesions

Elaine Soliven, 20190115000000

The non-steroidal phosphodiesterase-4 inhibitor crisaborole may reduce lesions in patients with mild-to-moderate atopic dermatitis (AD), according to an intrapatient randomized study presented at the Inflammatory Skin Disease Summit (ISDS) 2018.

Dupilumab improves concurrent asthma, sinonasal outcomes in AD

Audrey Abella, 20190114100000

Treatment with the human monoclonal antibody dupilumab led to improved asthma and sinonasal outcomes occurring concurrently with atopic dermatitis (AD), according to the results of a pooled analysis of four phase 3 trials* presented at ISDS 2018.

New topical agents on the horizon for eczema treatment

Pearl Toh, 20190112150000

Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.

What’s salt got to do with atopic dermatitis?

Elvira Manzano, 20190109114500

Patients with atopic dermatitis (AD) have elevated levels of sodium chloride or salt in their skin compared with those with nonlesional atopic and healthy skin, according to a new study finding which experts described as “provocative.”